Latest1 information on COVID-19

Clinical Trials Contact

About this Clinical Trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Your Message Will Go To

Martina Steffen

650-498-7061


All fields are required. *

Preferred contact method*

To:

Martina Steffen

650-498-7061



Go Back To The Trial

We were not able to send your contact info at this time.

Go Back To The Trial

©2022 Stanford Medicine